SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is receiving attention following reports that it proactively pulled jalapeños from some locations due to a potential link to a salmonella outbreak in Minnesota. While some traders are expressing concern over the potential for negative headlines to impact brand trust and sales, others view the pullback as a buying opportunity, noting the company's quick response and confirmation from health officials that there is no ongoing risk.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as investors debate whether recent expansion of its council partner network and interoperability proposals constitute meaningful long-term utility or merely persistent price weakness. While some traders continue to accumulate positions in anticipation of future regulatory clarity and tokenization adoption, others express frustration with sustained downward price action and compare the asset unfavorably to other market leaders.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is trending as investors debate its long-term viability, focusing on high cash burn rates, management's historical performance, and the potential for dilution despite positive revenue growth and recent technological advancements. Sentiment remains polarized, with bulls pointing to the commercial potential of the Eversense 365 system and institutional accumulation, while bears emphasize a history of reverse splits and concerns over operational execution.

Constellation Energy Corp. engages in the generation, supply, and marketing of clean electricity, and renewable energy products and solutions. The firm also offers wholesale energy, retail products and services. It operates under the following geographical segments: Mid-Atlantic, Midwest, New York, Electric Reliability Council of Texas (ERCOT), and Other Power Regions Segment. The company was founded in 1960 and is headquartered in Baltimore, MD.

Constellation Energy Corporation

Constellation Energy is receiving significant attention as investors react to a pullback in share price following the company's first-quarter earnings report. Despite the recent volatility and selling pressure, many traders remain bullish, pointing to the company's long-term nuclear power contracts and its role in supplying data centers as key catalysts for growth.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is attracting attention as traders speculate on the company's potential M&A activity to address looming patent cliffs for key drugs like Eliquis and Opdivo. The community is actively debating the likelihood of a major deal, with discussions centering on whether the company will prioritize bolt-on acquisitions or pursue larger, transformative mergers.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium is experiencing significant volatility as the community debates its long-term viability, with some traders citing potential short squeeze opportunities and adoption in city-wide network projects, while others express concerns over supply inflation, network utility, and past management decisions.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals is trending following a significant analyst upgrade and institutional accumulation, with market participants closely monitoring the upcoming CVS Caremark formulary decision and competitive dynamics with Aquestive Therapeutics. Discussions remain divided between those anticipating a major short squeeze and near-term catalysts, and others expressing skepticism regarding the company's high cash burn, aggressive spending, and long-term commercial execution.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors debate the platform's reliability, with many users citing frequent outages and glitches that hinder trading, while others defend the brokerage's long-term value and recent introduction of 24/7 crypto futures trading. Discussion remains fragmented between frustrations over technical stability and a competing narrative focusing on the company's asset growth and AI-driven expansion.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is trending as traders speculate on the potential for a rebound in leveraged exposure to MicroStrategy, with many debating the impact of upcoming reverse stock splits and the influence of volatile Bitcoin price action. While some community members view current low price levels as a buying opportunity, others warn of the risks associated with daily leveraged decay and the long-term deterioration of such ETFs.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Internet Computer (ICP) is experiencing significant community debate driven by persistent price weakness and concerns over long-term tokenomics, despite continued technical development and ecosystem activity. While some traders remain committed to its potential as decentralized infrastructure for AI and sovereign cloud applications, others express frustration with the lack of price appreciation and recent community sentiment shifts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Recent Setbacks Impact Growth Prospects of DNLI Stock?

Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.

Denali to Sell Priority Review Voucher for $195M Cash Boost

DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.

Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos

Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos...

• Reported GAAP EPS of -$0.68 up 5.56% YoY
• Reported revenue of $3.6M

Denali Therapeutics faces recurring operating losses, clinical trial failures such as the discontinued BIIB122 program, and ongoing risks related to the need for additional funding to support its future operations.

Denali Therapeutics achieved FDA approval and commercial launch for its first product, AVLAYAH, while strengthening its liquidity position through a $195 million voucher sale and a $200 million royalty agreement.

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Denali Therapeutics Inc

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

Equity

Bearish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.41	--	--	N/A
Q2 '26	-$0.51	-$0.68	-32.54%	MISSED
Q1 '26	-$0.72	-$0.69	4.61%	BEAT
Q4 '25	-$0.74	-$0.73	0.93%	BEAT
Q3 '25	-$0.75	-$0.74	1.02%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNLI Earnings

Latest Earnings Results: Q2 '26

Historical Earnings